HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Says Take Note: Document Supplement GMP Corrections

This article was originally published in The Rose Sheet

Executive Summary

FDA's latest supplement GMP warnings once again demonstrate the importance of appropriate documentation during manufacturing and in responding to questions from agency inspectors.

You may also be interested in...



Own-Labeler Lesson, Ingredient-Testing Lapse Noted Again In FDA Warnings

Sportron International "cannot contract out its ultimate responsibility to ensure that the dietary supplement it places into commerce" is compliant, and Absonutrix failed "to conduct at least one appropriate test or examination to verify the identity of a dietary ingredient," say FDA warning letters listing some of the most frequently noted problems found in GMP and labeling inspections.

GMP Documentation, Identity Testing Continue To Trip Supplement Firms

Warnings from FDA's Office of Regulatory Affairs make clear that failing to document compliance with each GMP requirement renders those parts of the process noncompliant. Warning letters posted March 22 also include FDA's latest enforcement against firms marketing bulk caffeine.

Rates Up, Guidance Absent: FSMA Re-inspection User Fees On Hold

Without a guidance for requesting fee reductions, FDA will not bill firms for re-inspections of facilities found non-compliant with manufacturing regulations or for costs linked to a firm failing to comply with a recall order.

Topics

UsernamePublicRestriction

Register

RS108591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel